Welcome to our dedicated page for Sensus Healthcare SEC filings (Ticker: SRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sensus Healthcare, Inc. (Nasdaq: SRTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical device manufacturer focused on superficial radiotherapy (SRT and IG-SRT) for skin cancer and keloids, Sensus uses these filings to report material events, financial results and governance changes.
Recent Form 8-K filings describe quarterly financial results, where Sensus discusses revenue, unit shipments of SRT systems, Fair Deal Agreement treatment volumes, and the use of non-GAAP metrics such as Adjusted EBITDA. Other 8-Ks outline board developments, including the appointment of independent directors and related committee assignments, with the company noting compliance with Nasdaq independence standards.
Through its SEC reports, Sensus Healthcare also furnishes earnings press releases that include reconciliations between GAAP and non-GAAP financial measures, along with commentary on reimbursement milestones. For example, the company has highlighted the establishment of dedicated CPT codes by the Centers for Medicare & Medicaid Services for superficial radiotherapy used in non-melanoma skin cancer, which it views as important to its commercial strategy.
On Stock Titan, AI-powered tools can help readers interpret these filings by summarizing complex sections, highlighting key figures and pointing out notable changes from prior periods. Users can quickly identify items related to results of operations, board appointments, and other material events, and use the filings archive to follow how Sensus Healthcare’s financial profile and corporate governance have developed over time.
Sensus Healthcare reported weakening sales and compressed margins in the quarter and year-to-date. Revenue was $7.3 million in Q2 and $15.7 million for the six months, declines of 20.7% and 21.1% versus prior-year periods driven primarily by fewer units sold to a large U.S. customer. Gross profit fell to $2.9 million in Q2 and $7.3 million YTD, and gross margin narrowed to 39.7% for the quarter (from 58.7%) and 46.5% YTD (from 60.8%).
Higher operating expenses outpaced revenue reductions: G&A, selling and marketing, and R&D all increased, with R&D up 127.8% YTD due to lobbying, added headcount and next-generation product development. The company recorded a net loss of $1.037 million in Q2 and a $3.609 million net loss for the six months, compared with net income in the prior-year periods.
Liquidity remains a stabilizing factor: cash and cash equivalents were $22.2 million and the amended revolving credit facility provides $15.0 million of available borrowing capacity with no outstanding borrowings, and the company was in compliance with credit covenants. Material risks disclosed include significant customer concentration (one U.S. customer represented 56% of Q2 revenue and 78% of receivables) and an ongoing DOJ inquiry for which potential costs cannot be estimated.